Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QN 165

Next Previous
X
Search
Drug Profile

QN 165

Alternative Names: ACT-GRO-777; AGRO-100; ALAN; AS-1411; QN-165

Latest Information Update: 18 Jul 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Alabama; University of Louisville
  • Developer Advanced Cancer Therapeutics; James Graham Brown Cancer Center; Qualigen Therapeutics; University of Louisville
  • Class Antineoplastics; Antivirals; Nucleotide aptamers; Oligodeoxyribonucleotides
  • Mechanism of Action Apoptosis stimulants; Nucleolin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Viral infections

Highest Development Phases

  • Discontinued Cancer; COVID 2019 infections; Neuroblastoma

Most Recent Events

  • 18 Jul 2022 QN 165 is available for licensing as of 18 Jul 2022. https://www.qualigeninc.com/pipeline/qn-165/
  • 05 Oct 2021 Discontinued - Phase-II for Cancer in USA (IV) (Qualigen Therapeutics pipeline, October 2021)
  • 05 Oct 2021 Discontinued - Preclinical for COVID-2019 infections in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top